Summit Therapeutics Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Summit is a clinical-stage biopharmaceutical company focused primarily on developing ivonescimab, licensed from Akeso for the United States, Canada, Europe and Japan. Both company-sponsored Phase III NSCLC trials, HARMONi and HARMONi-3, were enrolling patients. Amounts below are in U.S. dollars; financial figures are in millions unless stated otherwise.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $30.9 | $9.9 |
| General and administrative expense | $11.7 | $6.9 |
| Operating loss | $42.4 | $537.2 |
| Net loss | $43.5 | $542.4 |
| Basic and diluted loss per share | $0.06 | $1.43 |
| Net cash used in operating activities | $30.1 | $13.1 |
As a pre-revenue development-stage company, Summit reported no revenue; profit margins are not applicable. At March 31, 2024, cash and cash equivalents were $61.3, short-term U.S. Treasury investments were $95.4, and restricted cash was $0.3. Current assets were $163.3 and current liabilities were $23.4. Total liabilities were $132.6, including a $100.0 related-party promissory note; stockholders’ equity was $44.2. The company reported an accumulated deficit of $1,036.7.
Investing activities provided $19.9, principally reflecting Treasury maturities and purchases; financing activities provided $0.5 from employee stock awards. Cash, cash equivalents and restricted cash declined by $9.8 to $61.6. The company incurred $9.5 of stock-based compensation in the quarter.
Material changes versus the prior-year quarter
- R&D expense increased $21.0, primarily due to $18.3 more oncology spending on ivonescimab and higher compensation. Management expects oncology R&D costs to continue rising as development advances.
- G&A expense increased $4.8, primarily because stock-based compensation rose $5.3; lower legal and professional fees partly offset the increase.
- The Q1 2023 net loss included $520.9 of in-process R&D expense for the Akeso license upfront consideration. No comparable charge was recorded in Q1 2024; this largely explains the much smaller reported loss year over year.
- Operating cash use increased to $30.1 from $13.1. The 2023 comparison was affected by the license payment being presented in investing activities and by working-capital and other non-cash items.
- Other expense improved to $1.1 from $5.2, mainly reflecting lower interest expense on related-party notes.
Outlook, risks and contingencies
- Management estimates available cash and investments can fund operations through Q1 2025, but says additional capital is needed for ongoing operations and to repay the $100.0 related-party note, which matures April 1, 2025. Financing had not been secured as of the filing. The filing states these conditions raise substantial doubt about the company’s ability to continue as a going concern for at least one year from issuance of the financial statements.
- The note was amended in February 2024: interest accrues at the greater of 12% or the U.S. prime rate plus 3.5%, compounds quarterly, and is payable at maturity. Accrued interest was $1.7 at March 31, 2024.
- Akeso may receive up to $4.5 billion in regulatory and commercial milestone payments, plus low-double-digit royalties on licensed-territory net sales. The timing and likelihood of milestones and future sales are uncertain.
- Management expects to complete HARMONi enrollment in the second half of 2024. HARMONi-3 enrollment and expansion into additional regions depend on regulatory and review-board approvals; planned site expansion extends into early 2025.
- Key risks include clinical-trial timing and outcomes, regulatory requirements, manufacturing and supply arrangements, and the availability and terms of additional financing. Equity financing could dilute shareholders; debt or partnering could impose restrictions or require relinquishing rights.
- Prior development of ridinilazole and SMT-738 has been terminated; Summit says it will seek partnerships for those assets. The company reported no material legal proceedings and no material changes to the risk factors in its 2023 Form 10-K.
Important facts for investors to verify
- Whether Summit secures sufficient financing, on acceptable terms, to fund clinical programs and repay the related-party note by its April 1, 2025 maturity.
- Actual cash burn and runway relative to management’s estimate, including the impact of rising clinical-development costs.
- Enrollment progress, trial results and regulatory milestones for HARMONi and HARMONi-3, and any changes to expected timing or geographic scope.
- The terms, timing and potential dilution of any financing, and any related-party arrangements.
- Potential Akeso milestones, royalties and supply obligations as development and commercialization progress.
- Share count and potential dilution: 701,974,596 common shares were outstanding at March 31, 2024; the filing lists approximately 60.0 million potentially dilutive securities excluded from loss-per-share calculations as anti-dilutive.